Identification of tumor-associated macrophage subsets that are associated with breast cancer prognosis.
breast cancer
flow cytometry
macrophage
transcriptome
tumor microenvironment
Journal
Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
12
08
2020
revised:
06
11
2020
accepted:
20
11
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
31
12
2020
Statut:
ppublish
Résumé
Breast cancer is the leading cause of cancer-related deaths in women, demanding new treatment options. With the advent of immune checkpoint blockade, immunotherapy emerged as a treatment option. In addition to lymphocytes, tumor-associated macrophages exert a significant, albeit controversial, impact on tumor development. Pro-inflammatory macrophages are thought to hinder, whereas anti-inflammatory macrophages promote tumor growth. However, molecular markers to identify prognostic macrophage populations remain elusive. We isolated two macrophage subsets, from 48 primary human breast tumors, distinguished by the expression of CD206. Their transcriptomes were analyzed via RNA-Seq, and potential prognostic macrophage markers were validated by PhenOptics in tissue microarrays of patients with invasive breast cancer. Normal human breast tissue contained mainly CD206 Our data highlight the heterogeneity of tumor-infiltrating macrophages and suggest the use of multiple phenotypic markers to predict the impact of macrophage subpopulations on cancer prognosis. We identified novel macrophage markers that correlate with the survival of patients with invasive mammary carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer is the leading cause of cancer-related deaths in women, demanding new treatment options. With the advent of immune checkpoint blockade, immunotherapy emerged as a treatment option. In addition to lymphocytes, tumor-associated macrophages exert a significant, albeit controversial, impact on tumor development. Pro-inflammatory macrophages are thought to hinder, whereas anti-inflammatory macrophages promote tumor growth. However, molecular markers to identify prognostic macrophage populations remain elusive.
METHODS
METHODS
We isolated two macrophage subsets, from 48 primary human breast tumors, distinguished by the expression of CD206. Their transcriptomes were analyzed via RNA-Seq, and potential prognostic macrophage markers were validated by PhenOptics in tissue microarrays of patients with invasive breast cancer.
RESULTS
RESULTS
Normal human breast tissue contained mainly CD206
CONCLUSION
CONCLUSIONS
Our data highlight the heterogeneity of tumor-infiltrating macrophages and suggest the use of multiple phenotypic markers to predict the impact of macrophage subpopulations on cancer prognosis. We identified novel macrophage markers that correlate with the survival of patients with invasive mammary carcinoma.
Identifiants
pubmed: 33377644
doi: 10.1002/ctm2.239
pmc: PMC7719284
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e239Informations de copyright
© 2020 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
Références
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Cell. 2017 Apr 20;169(3):510-522.e20
pubmed: 28431249
Dev Biol. 2007 Aug 1;308(1):232-46
pubmed: 17597598
J Immunol. 2015 Aug 15;195(4):1858-67
pubmed: 26136428
J Immunol. 2017 Oct 1;199(7):2191-2193
pubmed: 28923980
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
J Exp Med. 2013 Oct 21;210(11):2477-91
pubmed: 24101381
J Clin Pathol. 1997 Aug;50(8):669-73
pubmed: 9301551
Future Oncol. 2020 Oct;16(29):2345-2356
pubmed: 32700568
J Cell Physiol. 2017 May;232(5):928-934
pubmed: 27791268
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Oncotarget. 2015 Apr 30;6(12):10284-96
pubmed: 25871398
Lancet Oncol. 2019 Mar;20(3):371-382
pubmed: 30765258
Oncotarget. 2017 May 2;8(18):30576-30586
pubmed: 28427165
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Genome Biol. 2009;10(11):R130
pubmed: 19919682
Nat Commun. 2019 Jan 17;10(1):281
pubmed: 30655530
J Biol Chem. 1994 Dec 9;269(49):31224-8
pubmed: 7983065
BMC Genomics. 2018 Sep 21;19(1):696
pubmed: 30241496
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Chem Neuroanat. 2004 Sep;28(1-2):51-65
pubmed: 15363491
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
J Cancer Res Clin Oncol. 2018 Dec;144(12):2319-2328
pubmed: 30128672
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
J Exp Med. 2017 Sep 4;214(9):2695-2713
pubmed: 28739604
J Pathol. 2002 Mar;196(3):254-65
pubmed: 11857487
Cancer Res. 1996 Oct 15;56(20):4625-9
pubmed: 8840975
J Cell Biochem. 2019 Mar;120(3):4634-4643
pubmed: 30320920
Mol Oncol. 2020 Oct;14(10):2384-2402
pubmed: 32671911
Mol Biol Cell. 2007 Oct;18(10):3810-9
pubmed: 17652460
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Int J Cancer. 2008 Aug 15;123(4):780-6
pubmed: 18506688
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Int J Mol Sci. 2019 Sep 09;20(18):
pubmed: 31505876
Clin Cancer Res. 2012 Jul 15;18(14):3762-71
pubmed: 22645050
J Immunol. 2008 Apr 15;180(8):5707-19
pubmed: 18390756
Eur J Immunol. 2009 Feb;39(2):514-26
pubmed: 19130475
Nat Cell Biol. 2020 May;22(5):546-558
pubmed: 32341550
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Elife. 2020 Jun 01;9:
pubmed: 32479261
Science. 2019 Mar 15;363(6432):
pubmed: 30872492
PLoS One. 2013 Nov 15;8(11):e80908
pubmed: 24260507
Int J Dev Biol. 2011;55(7-9):861-7
pubmed: 22161841
Cancers (Basel). 2020 Apr 08;12(4):
pubmed: 32276534
Nat Immunol. 2017 Jun;18(6):665-674
pubmed: 28459435
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Trends Cancer. 2019 Dec;5(12):822-834
pubmed: 31813459